Compass Therapeutics (CMPX) Shares Outstanding (2018 - 2026)

Compass Therapeutics' Shares Outstanding history runs 9 years deep, the most recent figure standing at $180.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 30.23% year-over-year to $180.1 million; the TTM figure through Mar 2026 stood at $180.1 million (up 30.23% YoY), while the FY2025 annual figure was $178.3 million, up 29.39% from the prior year.
• Shares Outstanding came in at $180.1 million for Q1 2026 at Compass Therapeutics, up from $178.3 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $180.1 million in Q1 2026 to a low of $100.9 million in Q1 2022.
• A 5-year average of $135.4 million and a median of $137.6 million in 2024 frame the typical range for Shares Outstanding.
• Across the five-year window, Shares Outstanding soared 96.65% in 2022 and increased 0.5% in 2025, its largest moves.
• Compass Therapeutics' Shares Outstanding stood at $126.3 million in 2022, then increased by 1.08% to $127.7 million in 2023, then rose by 7.95% to $137.8 million in 2024, then grew by 29.39% to $178.3 million in 2025, then advanced by 0.99% to $180.1 million in 2026.
• According to Business Quant data, Shares Outstanding over the past three periods registered $180.1 million, $178.3 million, and $177.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison